Clinical Trials Logo

Lung Diseases clinical trials

View clinical trials related to Lung Diseases.

Filter by:

NCT ID: NCT00852020 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Chronic Heart Failure and Chronic Obstructive Pulmonary Disease Patients

Start date: April 2009
Phase: N/A
Study type: Interventional

To test the compliance, tolerance, safety and to get preliminary insights into the efficacy of a new oral nutritional supplement (containing n-3 fatty acids, amino acids and antioxidants) designed to prevent or delay cachexia and anorexia in patients with chronic heart failure (CHF) or chronic obstructive pulmonary disease (COPD).

NCT ID: NCT00851695 Completed - Asthma Clinical Trials

Examining the Role of Vitamin D in Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Start date: July 2007
Phase: N/A
Study type: Observational

Asthma and chronic obstructive pulmonary disease (COPD) are diseases that affect a person's ability to breathe normally. People who do not receive enough vitamin D may have a higher risk of developing asthma or COPD. This study will examine previously collected blood samples of participants in three studies to determine whether people with low vitamin D levels have an increased risk of severe asthma or COPD.

NCT ID: NCT00851370 Withdrawn - Clinical trials for Pulmonary Disease, Chronic Obstructive

Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels

Start date: January 2009
Phase: Phase 2
Study type: Interventional

The objective is to conduct an exploratory study on the effect of Omalizumab on COPD patients with elevated IgE. Exploratory outcomes include to determine whether Omalizumab use: reduces exacerbations in COPD patients; or improves rescue medication use, decreases ICS use, modified Medical Research Council (MMRC) dyspnea score, St. George's Respiratory Questionnaire (SGRQ), 6-minute walk distance (6MWD), forced expiratory volume at one second (FEV1)(the latter 3 with BMI make up the BODE score), residual volume (RV), total lung capacity (TLC), exhaled nitric oxide (ENO), and determination C-reactive protein (CRP).

NCT ID: NCT00850863 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Systemic Inflammation in Chronic Obstructive Pulmonary Disease (COPD)

Start date: February 2009
Phase: N/A
Study type: Observational

COPD is ranked number 3 by the WHO list of important diseases worldwide and is the only disease with increasing mortality. The pathogenesis of cigarette smoke-induced COPD is obscure, therefore more insight is needed to design effective anti-inflammatory agents. Recently it has become clear that cigarette smoke-induced inflammation is not only present in the lungs but also in the blood, and that this systemic inflammation has important consequences for the clinical expression of COPD. The investigators hypothesize that healthy individuals who are susceptible to cigarette smoking demonstrate a higher and aberrant systemic inflammatory response to cigarette smoke. This susceptibility is caused by heterogeneous factors and is associated with various polymorphic genes that interact with each other and with the environment. Objective: - To study systemic inflammation in individuals who are or are not susceptible to develop COPD. - To characterize the switch to chronicity of the systemic inflmmatory response in COPD - To determine whether the type and severity of the systemic inflammation contributes to the clinical outcome of COPD - To compare between subjects who are or are not susceptible to develop COPD in peripheral blood, the corticosteroid responsiveness in vitro, and to unravel underlying mechanisms. - To study the role of candidate genes that may play a role in the development of fixed airway obstruction, and to identify clues for patient's responsiveness to specific drugs - To develop new biological and clinical markers for the early diagnosis and monitoring of COPD - To define possible mediators involved in the early induction of COPD in susceptible smokers, and to define new drug targets

NCT ID: NCT00846768 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD

Start date: February 2009
Phase: Phase 2
Study type: Interventional

The primary objective of the trial is to determine the effect of BI 17444Cl on the lung function over a 24-hour period, when it is inhaled using the Respimat inhaler in patients with chronic obstructive pulmonary disease. In the trial four treatments of each 3 weeks of duration are included: 2 dosages in a once daily administration and 2 dosages for administration twice daily.

NCT ID: NCT00846586 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

INTRUST1
Start date: March 2009
Phase: Phase 3
Study type: Interventional

This study assessed the efficacy and safety of indacaterol (150 µg once daily [od]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease (COPD)

NCT ID: NCT00846573 Terminated - Healthy Clinical Trials

Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders

Start date: November 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to test the efficacy of Hyperpolarized Helium-3 gas in MR imaging in COPD, asthmatics, CF and healthy volunteers.

NCT ID: NCT00846287 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Assessment of Arformoterol for Chronic Obstructive Pulmonary Disease (COPD) Using Hyperpolarized 3He MRI

Start date: November 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to determine efficacy of MR imaging with hyperpolarized helium-3 gas in COPD patients both before and after treatment.

NCT ID: NCT00843414 Completed - Lung Disease Clinical Trials

Immunological Characterization of Bronchoalveolar Cells in Normals

Start date: March 1978
Phase: N/A
Study type: Observational

To obtain the monocytes (white blood cells) from normal volunteers for the purpose of studying how proteins, fats, carbohydrates, as well as RNA and DNA for gene expression, relate to immunity. This information will be compared to other studies in patients with lung diseases such as Emphysema, Sarcoidosis, and Interstitial Pulmonary Fibrosis.

NCT ID: NCT00841971 Completed - Mycoses Clinical Trials

Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients

Start date: February 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the efficacy of anidulafungin versus fluconazole for the prevention of fungal diseases in liver transplant recipients